晚期非小细胞肺癌免疫治疗:研究进展和展望OACSTPCD
Immunotherapy for Advanced Non-small Cell Lung Cancer:Research Progress and Perspectives
免疫治疗已经改变了晚期非小细胞肺癌(NSCLC)的治疗格局,在一线及后线治疗中均显现出巨大潜能.同时,随着免疫治疗的广泛应用,仍有许多问题需要进一步探讨,如疗效预测生物标志物的探索、免疫治疗模式的优化、免疫相关不良反应和特殊人群的管理等.本综述梳理了晚期NSCLC免疫治疗的研究进展,并探讨了面临的挑战和未来发展方向.
Immunotherapy has changed the treatment landscape of advanced non-small cell lung cancer(NSCLC),showing great potential in the treatment of untreated and relapsed or refractory(R/R)patients.However,numerous issues that need further exploration remain with the wide application of immunotherapy.They include the exploration of biomarkers for efficacy prediction,the optimization of immunotherapy modalities,immune-related adverse effects,and the management of special populations.This review summarizes the progress of the research on immunotherapy for advanced NSCLC and discusses its challenges and future directions.
王婧怡;钟雨玲;邬麟
410013 长沙,湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院胸内二科421001 衡阳,南华大学衡阳医学院,湖南省肿瘤医院研究生协作培养基地
临床医学
非小细胞肺癌免疫治疗免疫检查点抑制剂
Non-small cell lung cancerImmunotherapyImmune checkpoint inhibitors
《肿瘤防治研究》 2024 (006)
409-418 / 10
湖南省科技创新计划(2023SK4024、2021SK51121);湖南省肿瘤医院"科研攀登计划"(2X2020005-5);北京市希思科临床肿瘤学研究基金会(Y-2019Gene-cast-024) The Science and Technology Innovation Program of Hunan Province(No.2023SK4024,No.2021SK51121);Hunan Cancer Hospital Climb Plan(No.2X2020005-5);Beijing Xisike Clinical Oncology Research Foundation(No.Y-2019Genecast-024)
评论